| Company* | Product | Description | Indication | Status (Date) |
| | ||||
| CANCER | ||||
| Active Biotech | TTS | Tumour Targeted Superantigens | Renal cell cancer | Company plans to start a Phase II trial in the UK in December (11/19) |
| Collgard Bio- | Halofugi- | Orally bioavailable inhibitor of the synthesis of collagen Type 1 and collagenase | Advanced-stage cancer | The first patient was enrolled in a Phase I/II trial in Europe (11/28) |
| Gilead Sciences | GS | Anticancer nucleoside analogue | Cancer | Company initiated a Phase I trial in Canada (11/14) |
| Gilead Sciences | GS | Liposomal thymidylate synthase inhibitor | Cancer | Company began a Phase I trial in Germany (11/28) |
| Immuno- | MAK | IDM-activated macrophage cells | Bladder cancer | Phase I/II trial data showed the therapy significantly reduced tumor recurrence; study was conducted in France (11/19) |
| Matrix Pharma- | IntraDose Injectable Gel | Biodegradable gel containing cisplatin and epinephrine | Recurrent or refractory head | Company submitted an application in Europe for the approval of the gel (11/26) |
| NeoOncoRx | Neoquin | Anticancer compound administered with intravesical installations | Bladder cancer | Company opened enrollment for a Phase I/II study in England (11/2) |
| PhotoCure ASA | ¿ | Photodynamic therapy | Basal cell carcinoma | Phase III results from a trial in Australia showed that 89% of lesions disappeared completely three months after treatment (11/16) |
| Progen | PI-88 | Anticancer therapeutic; sulfated oligosaccharide | Multiple | Company was granted approval to begin a Phase II trial in Australia (11/8) |
CENTRAL NERVOUS SYSTEM | ||||
| Angiotech | Paxceed | Systemic formulation of Micellar Paclitaxel | Secondary progressive | Company was given permission in Canada to extend its Phase II study for another year, enrolling another 100 patients (11/26) |
| Phytopharm | P58 | Oral treatment; derived from from a family of chemicals found in a traditional Asian plant-based tonic for the elderly | Dementia | Company started a Phase I/II trial in women older than 55 (11/14**) |
| DIABETES |
||||
| Biotech | DIAB II | Novel insulin-receptor sensitizer; tablet form | Diabetes | DIAB II received regulatory approval in Peru (11/6) |
| Peptor Ltd. | DiaPep | Synthetic version of p277, a peptide derived from hsp60, a 60kDa heat shock protein | Type I | Phase II results showed DiaPep277 arrested the progression of Type I diabetes, prevented the destruction of insulin-producing pancreatic cells, and reduced the need for injected insulin in newly diagnosed patients (11/26) |
INFECTION | ||||
| BioMedicines | ¿ | Omega interferon | Hepatitis C | Phase II interim results showed that omega interferon can reduce HCV to undetectable levels in interferon-naive patients having any of the four major HCV genotypes; the study was conducted in Europe (11/12) |
| Hollis-Eden | HE2000 | Immune-regulating | Plasmodium falciparum malaria infection | Phase II results from a study in Thailand showed that 17 of 21 patients achieved clearance of all malarial parasites (11/12) |
| ICN Pharma- | Rebetol | Ribavirin | Hepatitis C | Rebetol was approved in Japan for use in combination with interferon alfa-2b injection (11/27) |
| Oxxon | ¿ | Virus pharmaccine candidate | Hepatitis B | Company initiated Phase I trials (11/5) |
| MISCELLANEOUS |
||||
| Cambridge | CAT-152 | Lerdelimumabin; human anti-TGFB monoclonal antibody | Patients undergoing surgery for glaucoma and cataract | Phase II results showed the drug was safe and well tolerated (11/14) |
| La Jolla | LJP 394 | Molecule (toleragen) that binds to the surface of B cells and shuts off production of antibodies to double-stranded DNA | Lupus kidney disease | European Commission granted orphan medicinal product designation in the European Union (11/28) |
| NexMed | Alprox- | Incorporates alprostadil with the NexACT transdermal delivery technology | Erectile | NexMed's Asian licensee filed an NDA seeking approval in Singapore (11/27) |
| | ||||
| Notes: | ||||
| * Privately held |
||||
| ** Denotes the date the item ran in BioWorld International. |
||||
| Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. |
||||
| CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
| NDA = New Drug Application |
||||
